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EDITORIAL
Rapamycin eluting stent: the onset of a new era in
interventional cardiology
P W Serruys, E Regar, A J Carter
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Drug eluting stents represent one of the fastest growing
fields in interventional cardiology today.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
At the congress of the European Society ofCardiology in Amsterdam in 2000, I (PWS)was asked to give the Andreas Gruentzig
Lecture. In the week preceding the lecture, we
re-angiographied patients 32 and 33 of the initial
cohort of patients who had received a rapamycin
eluting stent in Sao Paulo and in Rotterdam.
Scrutinising the 4–6 month angiographic and
ultrasonic results of these patients, I became
overwhelmingly convinced that we were the
privileged witnesses of a new phenomenon: the
almost complete abolition of intra-stent neointi-
mal proliferation. Colleagues, invasive and non-
invasive cardiologists, old friends, and financial
analysts were surprised by the unusual “excess of
enthusiasm” coming from somebody who has
built over the years a reputation as a critical
assessor, never one to be carried away by the hype
of a new wave in interventional cardiology. In the
history of this field I have recognised (and “got
excited” by, as my American colleagues used to
put it) only two revolutionary developments: the
introduction of the moveable and steerable
guidewire by John Simpson, and the advent of the
stent (Palmaz-Schatz, Wallstent). The drug elut-
ing stent is the third such development, and
almost one year later I would like to restate the
fact that we are entering a new era in interven-
tional cardiology. Why? Because the principle of
an eluting stent is sound, and because the three
major technical challenges have been mastered—
the controlled release of an efficient drug from a
stable coating.
THE PRINCIPLE
Drug administration for the prevention of rest-
enosis has been tested in the past—with disap-
pointing results throughout. A proposed explana-
tion for the repeated failure of clinical drug
studies has been that agents given systematically
cannot reach sufficient concentrations in injured
arteries, which has a signficant impact on the
restenotic process. Local drug administration
offers advantages. The active drug is applied to
the vessel at the precise site and at the time of
vessel injury. Local drug delivery is able to achieve
higher tissue concentrations of the drug. No
additional material or procedures are required.
Systemic release is minimal and may reduce the
risk of remote systemic toxicity.
THE DELIVERY VEHICLE
The delivery vehicle must fulfil pharmacological,
pharmacokinetic, and mechanical requirements.
The release of the drug into the vessel must take
place in a manner that is consistent with the
drug’s mode of action. Drug release must be pre-
dictable and in a controlled concentration and
time. The delivery vehicle must be suitable for
sterilisation; it must follow the geometric change
of configuration during stent expansion and
resist mechanical injury caused by the inflation of
the balloon. Today these problems are controlled,
guaranteeing intact coating during clinical appli-
cation.
THE DRUG
The drug should be one that inhibits the multiple
components of the complex restenosis process.
Uncontrolled neointimal tissue accumulation
shows some parallels to tumour growth, thus the
use of antitumorous strategies seems to be a logi-
cal consequence. Numerous pharmacological
agents with antiproliferative properties have been
tested for their potential to inhibit restenosis.
Rapamycin (sirolimus) has been approved by
the US Food and Drug Administration for the
prophylaxis of renal transplant rejection. It is a
naturally occurring macrocyclic lactone which is
highly effective in preventing the onset and
severity of disease in several animal models of
autoimmune disease, such as insulin dependent
diabetes mellitus, systemic lupus erythematosus,
and arthritis.
RAPAMYCIN’S MECHANISM OF ACTION
The class of macrocyclic immunosuppressive
agents (rapamycin, cyclosporin A, tacrolimus
FK506) bind to specific cytosolic proteins called
immunophilins (for example, FK506 binding
protein 12) to gain their immunosuppressive
activity. Rapamycin blocks G1 to S cell cycle pro-
gression by interacting with a specific target pro-
tein (mTOR, mammalian target of rapamycin)
and inhibits its activation. The inhibition of
mTOR suppresses cytokine driven (IL-2, IL-4,
IL-7, and IL-15) T cell proliferation. mTOR is a key
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regulatory kinase and its inhibition has several important
effects, including: the inhibition of translation of a family of
mRNAs that code for proteins essential for cell cycle progres-
sion; the inhibition of IL-2 induced transcription of proliferat-
ing cell nuclear antigen (PCNA) that is essential for DNA rep-
lication; the blocking of CD28-mediated sustained
upregulation of IL-2 transcription in T cells; and the inhibition
of the kinase activity of the cdk4/cyclinD and cdk2/cyclinE
complexes, essential for cell cycle progression. The mechanism
of action is distinct from other immunosuppressive drugs that
act solely by inhibiting DNA synthesis, such as mycophenolate
mofetil and azathioprine. Rapamycin is synergistic with
cyclosporin A and has much lower toxicity than other immu-
nosuppressive agents.
Rapamycin prevents proliferation of T cells but also
proliferation1 and migration of smooth muscle cells. Gregory
and colleagues demonstrated that intraperitoneal administra-
tion of rapamycin resulted in a dose dependent inhibition of
arterial intimal thickening caused by either chronic alloim-
mune or mechanical injury in a rat model.2 3 Subsequent stud-
ies reported that rapamycin inhibited both human and rat
vascular smooth muscle cell proliferation in vitro by blocking
G1/S transition. The inhibition of proliferation was mediated
by rapamycin binding to its cytosolic receptor, FK506 binding
protein 12, and associated with reduced cdk2 activity and pro-
tein retinoblastom phosphorylation.4 5
Gallo and colleagues recently showed that systemic
rapamycin treatment significantly reduces the proliferative
response after coronary angioplasty in the porcine model.6 The
antiproliferative effects of rapamycin after angioplasty were
attributed to an inhibition of the pRB phosphorylation
preventing the down regulation of p27kip1. Thus, the antiprolif-
erative activity of rapamycin after balloon arterial injury in
conjunction with its immunosuppressive properties suggests
that this drug could also be useful for the prevention of
in-stent restenosis.
This hypothesis is further supported by findings in human
carotid arteries.7 A robust upregulation of FK506 binding pro-
tein 12 was detected in the neointimal tissue of restenotic
lesions, whereas no FK506 binding protein 12 was detectable
in smooth muscle cells from control media.
THE RAPAMYCIN ELUTING STENT
The rapamycin coated BX Velocity stent is fabricated from
medical 316 LS stainless steel. It is available in a length of
18 mm and in two cell configurations (6 cell configuration:
expanded diameter 2.5–3.25 mm) and 7 cell design (expanded
diameter 3.5–3.75 mm). The stent contains 140 µg rapamycin/
cm2 which gives a total rapamycin content of 153 µg on the
6 cell stent and 180 µg on the 7 cell stent. The coating formu-
lation consists of 30% rapamycin by weight in a 50:50 mixture
of the polymers polyethylenevinylacetate (PEVA) and poly-
butylmethacrylate (PBMA).
IN VIVO PHARMACOKINETICS
In vivo pharmacokinetics studies in the porcine coronary
model demonstrated that the whole blood concentration of
rapamycin peaks at 1 hour (mean (SD) 2.63 (0.74) ng/ml)
after stent deployment and then declines below the lower
limit of detection (0.4 ng/ml) by three days. The total arterial
tissue concentration of rapamycin is 97 (13) ng/artery and the
residual stent content is 71 (10) µg at three days. The amount
of residual rapamycin on the stent at three days is 43% of the
initial quantity loaded on the stent. A modification of the
coating provides similar arterial tissue concentrations at 28
days. These data document the ability to deliver and achieve a
potentially therapeutic arterial tissue concentration of ra-
pamycin in the porcine model and insignificant concentra-
tions in the systemic circulation using the non-erodible meth-
acrylate and ethylene based copolymer matrix.
PRECLINICAL EFFICACY STUDIES
Preclinical efficacy studies demonstrated a 35–50% reduction
in in-stent neointimal hyperplasia for the rapamycin coated
stents as compared with bare metal stents at 28 days in the
porcine and rabbit model.8 Histological assessment revealed
the presence of typical cellular components of the neointima
and a similar degree of re-endothelialisation for the rapamy-
cin as compared with the bare metal stents. The morphology
of non-stented reference arterial wall sections, including the
vessel area, neointimal area, and per cent area stenosis was
similar for the metal and each of the drug coated stents. A
semiquantitative histological grading system demonstrated
less smooth muscle cell colonisation and more residual fibrin
deposition for the rapamycin eluting stents as compared with
the bare metal stents. Therefore, critical reparative events,
such as endothelialisation and smooth muscle cell colonisa-
tion of the neointima, with rapamycin eluting stents occur in
a similar temporal sequence as observed with bare metal
stents. The focal remnants of residual fibrin deposition
observed in the vessel with rapamycin coated stents may
reflect a delay in arterial repair or impaired fibrin degradation
secondary to the local effects of the drug.
CLINICAL DATA
The first clinical application of the rapamycin coated stent was
performed in Sao Paulo and Rotterdam. Thirty patients with
angina pectoris were electively treated with two different for-
mulations of the rapamycin coated BX Velocity stent (Cordis)
(slow release [SR] n = 15, and fast release [FR], n = 15). All
stents were successfully delivered, and patients were dis-
charged without clinical complications. At four months’ follow
up, there was minimal neointimal hyperplasia in both groups
as assessed by IVUS and quantitative coronary angiography
(in-stent late loss, 0.09 (0.03) mm [SR] and 0.02 (0.3) mm
[FR]). No in-stent or edge restenosis was observed. No major
clinical events (stent thrombosis, repeat revascularisation,
myocardial infarction, death) had occurred by 12 months.9 At
one year follow up, IVUS volumetric analysis and angiography
indicated minimal amounts of neointimal hyperplasia that
were scarcely different from the four month data in both
groups, with some patients showing no evidence of hyperpla-
sia whatsoever. There were no major adverse cardiac events
and no restenosis in either of the groups. One late acute myo-
cardial infarction occurred in the FR group at 14 months.10 In
Rotterdam,15 patients were treated, and quantitative angio-
graphy and three dimensional quantitative IVUS were
performed at implantation and at six months’ follow up. All
stent implantations were successful; one patient died on day 2
of cerebral haemorrhage and one patient suffered subacute
stent occlusion caused by edge dissection. At nine months’
follow up no further adverse events had occurred and all
patients were angina-free. Quantitative coronary angiography
revealed essentially no change in minimal lumen diameter
and per cent diameter stenosis by angiographic criteria, and
hence no in-lesion or in-stent angiographic restenosis was
observed. Quantitative ultrasound showed that intimal hyper-
plasia volume and per cent obstruction volume at follow up
were negligible (5.3 mm3 and 1.8%, respectively). No edge
effect was observed in the segment proximal and distal to the
stent.11
These first clinical results are spectacular, as they convinc-
ingly demonstrate the absence of neointimal proliferation in
all patients within the first six months after coronary stent
implantation, a phenomenon which has never been reported
in the past. If this promise—namely, the elimination of
restenosis—becomes reality we will witness the onset of a new
era in interventional cardiology and the revolution of catheter
based intervention, bypass surgery, and health care econom-
ics! These enormous potential implications are the key for
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today’s enthusiasm. However, more than 20 years of experi-
ence in the investigation of restenosis force us to think of a
possible Achilles’ heel. In fact, a lot of unanswered questions
still have to be resolved. First of all, controlled clinical data are
needed. Furthermore, long term studies are required to eluci-
date if the drug is permanently inhibiting neointima growth
or simply delaying the formation of neointima. Additionally,
the recent experience with vascular brachytherapy alerts us to
search for “unexpected” phenomena such as positive remod-
elling, late stent malapposition, edge effect, or late thrombosis.
Again, meticulous long term clinical, angiographic, and IVUS
follow up will be mandatory.
ONE YEAR LATER: DOES THE RAVEL STUDY REVEAL
THE FULL STORY?
The randomised study RAVEL, using the rapamycin coated BX
Velocity balloon expandable stent in the treatment of patients
with de novo lesions in native coronary arteries, is a
multicentre, prospective, randomised double blind clinical
trial comparing a bare metal stent with the drug coated stent.
Two hundred and twenty patients were randomised to a single
rapamycin coated stent (140 µg/cm2) versus a bare metal BX
Velocity stent. At six months’ follow up, the restenosis rate of
the treated group was zero, the loss in minimal lumen diam-
eter was zero, there was no target lesion reintervention, and
the event-free survival was 96.5%.12
UPCOMING CLINICAL TRIALS
The SIRIUS study is a multicentre, prospective, randomised
double blind trial that is being conducted in 55 centres in the
USA. Eleven hundred patients with focal de novo native
coronary arterial lesions (2.5–3.5 mm diameter, 15–30 mm
long) will be randomised to treatment with rapamycin coated
or bare metal BX Velocity balloon expandable stents. The pri-
mary end points of the SIRIUS trial are target vessel failure
(death, myocardial infarction, target lesion revascularisation)
at nine months. In addition, secondary end points are core
laboratory analysis of angiographic and IVUS data to
determine treatment effects on neointimal hyperplasia and
in-stent restenosis. Clinical follow up will extend to three
years in order to assess for late events. In addition to the piv-
otal RAVEL and SIRIUS trials, feasibility studies are ongoing
to assess efficacy of rapamycin coated stents in more complex
lesion subsets such as in-stent restenosis.
Drug eluting stents represent one of the fastest growing
fields in interventional cardiology today. The exploitation of
different classes of drugs which are potential candidates for
the inhibition of restenosis, in combination with novel drug
delivery systems or local gene therapy (for example, local
expression of proliferation regulatory genes, transfer of
cytotoxic genes, vascular endothelial growth factor (VEGF))
will continue. The multicentre trials will help to answer some
of the most important clinical questions and determine
whether this really reflects the eve of a “new era” or just a
“new vogue” in interventional cardiology.
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